Vector Sciences Inks Peptide Manufacturing Deal for $80.8B Market

Vector Sciences & Therapeutics (TSXV: PAIN) has entered a three-year development and manufacturing agreement with MPP Group LLC, a Wisconsin-based contract development and manufacturing organization (CDMO), to develop and produce pharmaceutical-grade peptide formulations — a deal that brings commercial-scale manufacturing infrastructure to a market still adjusting to the FDA’s April reclassification.

The agreement, originally announced May 11 but updated with corrections on May 19, co-locates compound formulation, analytical testing, and Vector’s proprietary transdermal delivery platform within a single FDA-registered, cGMP-compliant facility in Mequon, Wisconsin. The arrangement supports development of 22 novel shelf-stable peptide formulations targeting the $80.8 billion global peptide market, according to the company.

What the deal includes

Under the three-year term, MPP provides Vector access to an existing facility representing approximately $6 million in capital expenditure that Vector avoids duplicating. Vector funds peptide-manufacturing equipment dedicated exclusively to its products and retains ownership, with the right to take possession if the agreement terminates.

The companies will jointly develop:

• Novel peptide formulation development for 22 peptides
• Purity and potency test methods
• Aseptic manufacturing of pharmaceutical-grade peptides in defined milligram quantities

The stated goal is shelf-stable formulations with up to 24-month stability for compounds including BPC-157, TB-500, PT-141, Sermorelin, CJC-1295, Ipamorelin, MOTS-c, GHK-Cu, DSIP, and KPV — six of which (BPC-157, TB-500, MOTS-c, GHK-Cu, DSIP, and KPV) are among the 12 peptides the FDA reclassified to Category 2 on April 15.

The Category 2 context

The press release states that 14 of the 22 peptides were “recently removed by the FDA from the Category 2 list” — terminology that aligns with the FDA’s April 15 action, which removed 12 peptides from Category 2 of the 503A bulk drug substances evaluation framework. Being removed from Category 2 means these peptides are no longer in the “pending nomination with safety concerns” freeze tier and can now be compounded under valid patient-specific prescriptions — though their final placement remains subject to the July PCAC meeting decision.

The Vector Sciences release also lists PT-141 (bremelanotide), Sermorelin, CJC-1295, and Ipamorelin among its 22 formulations — peptides that were not part of the April 15 action and operate under different regulatory frameworks, bringing the total to approximately 14 compounds that have recently gained or maintained compounding eligibility.

PeptidesBeat has not independently verified the specific list of 14 compounds the release references, nor whether any additional peptides beyond the April 15 group have received updated Category 2 status. Readers should treat the 14-compound figure as potentially including the 12 April-reclassified peptides plus PT-141, Sermorelin, CJC-1295, and Ipamorelin — which were always available through compounding under different regulatory pathways.

Industry infrastructure builds

Regardless of the Category 2 ambiguity, the Vector Sciences-MPP agreement represents the first publicly announced commercial-scale peptide manufacturing deal since the April reclassification reshaped the compounding landscape. The arrangement signals that private-sector investment in pharmaceutical-grade peptide production infrastructure continues despite — or perhaps because of — the regulatory uncertainty.

The partnership also highlights a growing bifurcation in the peptide market: companies investing in FDA-registered, cGMP-compliant manufacturing versus the research-chemical gray market that has drawn increasing FDA enforcement attention.

Market context

The $80.8 billion global peptide market estimate cited in the release encompasses therapeutic peptides, cosmetic peptides, and research-grade compounds. The deal’s focus on pharmaceutical-grade, shelf-stable formulations positions Vector to serve the physician-supervised use channel — a distribution model that has gained traction as major media outlets and safety organizations like ECRI and ISMP have raised concerns about quality control in the unregulated peptide market.

The partnership comes as palatable manufacturing solutions and AI-driven peptide development continue to attract investment, suggesting the peptide sector is evolving from a compounding-centric model toward a more structured pharmaceutical manufacturing ecosystem.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.